Cookies auf der KCI-Website
Wir verwenden Cookies, um Ihnen die Nutzung unserer Website zu erleichtern. Weitere Informationen zu Cookies und deren Verwendung erhalten Sie hier Privacy Policy. Um Ihnen das Navigieren zu erleichtern, empfehlen wir Ihnen, die Cookies zu akzeptieren.
Hilfe zu Eingabehilfen | Sitemap | Kontaktieren Sie uns | Kundendienst ANRUF: 01/86330
Österreich Change Country
Startseite  |  Einsatzgebiete  |  Produkte  |  Klinische Evidenz  |  Fortbildung and Training  |  Für Patienten  |  Kundendienst
Sie sind hier: Startseite > Nachrichten & Medien > Acelity Expands TIELLE™ Advanced Foam Dressing Portfolio in Europe

Acelity Expands TIELLE™ Advanced Foam Dressing Portfolio in Europe

Freigegeben : 18 November 2015

TIELLE Silicone Border combines proven absorption technology with a soft silicone adhesive; provides clinicians a new option to minimize pain and trauma for patients living with wounds

KCI, Leader in Advanced Wound Care Solutions
SAN ANTONIO, November 18, 2015 – Acelity announced today that its TIELLE™ Silicone Border, a soft, conformable wound care dressing product in the TIELLE Family range, is now available in Europe. This new adhesive foam dressing combines Acelity’s proven LiquaLockTM Advanced Absorption Technology with a new soft silicone adhesive in order to maintain an optimal healing environment and provide for gentle removal of the wound care dressing. Acelity expects to introduce the TIELLE Silicone Border to other markets in 2016.
The TIELLE Silicone Border is intended to manage a range of exudate levels and partial or full thickness wounds. The soft silicone adhesive spans the full extent of the dressing, allowing for gentle removal, minimizing pain and trauma for the patient. The TIELLE Family range retains more fluid than other foam dressings, minimizing the risk of skin maceration. The TIELLE Silicone Border can be worn for up to seven days depending on wound condition and exudate level and is designed to help reduce the number of dressing changes, a benefit for patients, payors and providers. 
“The TIELLE Silicone Border is an important option because patients with wounds requiring advanced dressings often face painful dressing changes,” said Keith Harding, CBE, Wound Healing Research Unit, Cardiff University. “The new soft silicone adhesive of the TIELLE Silicone Border helps maintain an optimal wound healing environment, minimizing pain and risk of skin maceration, even under the pressures exerted by compression bandaging.”
“The availability of TIELLE Silicone Border marks an expansion of our wound dressing offering and complements our existing line of advanced wound therapeutics in Europe,” said Joe Woody, president and chief executive officer of Acelity. “This is part of our continued commitment to introduce new options to the TIELLE range that meet unique patient needs. We will continue to leverage our deep expertise in this area to position Acelity as the solutions provider of choice for clinicians both in Europe and around the world.” 
TIELLE Silicone Border is suitable for use on fragile skin and sensitive peri-wound skin, including low to highly exuding, partial or full thickness wounds. Additionally, it may be used on a variety of wounds, including low extremity ulcers (venous, arterial, mixed aetiology), decubitus (pressure) ulcers, donor sites, traumatic and post-surgical wounds. It can also be used as a secondary dressing in combination with other primary dressings, such as bioresorbable products or antimicrobials.
About Acelity 
Acelity L.P. Inc. and its subsidiaries are a global advanced wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. Available in more than 75 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,700 people around the world. 
For more information, contact:
Kathryn Skeen
Corporate Communications
Phone: +1-210-882-2067
Caleb Moore
Investor Relations
Phone: +1-210-255-6433

  • Share on
  • Share on Twitter
  • Besuchen Sie unsere YourTube Seite

Wichtige Mitteilung für Patienten

Rechtliches | Datenschutzrichtlinien | Kontaktieren Sie uns | Impressum

© 1998 - 2013 KCI Licensing, Inc. Alle Rechte vorbehalten.    DSL# 09-03-193.AT
Die Informationen auf dieser Website wurden ausschließlich zur Nutzung in Österreich/ KCI Austria GmbH bereitgestellt. Diese Website enthält Informationen über Produkte, die möglicherweise nicht in allen Ländern verfügbar sind. Es ist außerdem möglich, dass sie von den zuständigen Behörden in bestimmten Ländern noch nicht oder nicht für bestimmte Indikationen zugelassen sind.